EVALUATION OF THE SYNERGISTIC EFFECT OF A NOVEL LENTUSCIN-VANCOMYCIN ANTICANCER AGENT

Vancomycin's declining efficacy against clinical Staphylococcus isolates has sparked worries about the limited availability of antibiotic therapy alternatives. Novel treatments, such as several promising antimicrobial peptides, have come into focus in response. Notably, several experimental investigations have demonstrated the strong biological activity of specific bacteriocins, indicating selective cytotoxicity by specifically targeting distinct cancer cell types in addition to their ability to combat bacterial pathogens. This study succinctly summarizes its objectives, methods, results, and conclusions. The alternative synergistic combination of vancomycin and lentuscin for treating the cancer cell line WRL68 decreased both the cell viability and the IC50 values of A375. The goal of this study was to compare the antimicrobial activity of bacteriocin from Staphylococcus lentus with that of a combination of vancomycin and lentuscin (bacteriocin produced from Staphylococcus lentus). Pathogens like S. lentus were isolated from clinical samples (e.g., mid-stream urine). It is essential to create a novel antimicrobial agent that is synergistic with the antibiotic vancomycin and that has been evaluated for mammalian cell cytotoxicity. The bacteriocin was produced in modified media supplemented with 1% glucose at 37°C for 72 hr with an inoculum size of 1.2 ˟ 109 CFU/ml and a pH of 7. The important steps for the extraction of the bacteriocin were purification with 70% ammonium sulfate salt and purification by DEAE-cellulose chromatography. The alternative synergistic drug vancomycin, combined with lentuscin for treating the cancer cell line, Cell line derived from embryonic liver (WRL68 ), decreased the cell viability and IC50 values of A375. Conclusion This is the first report demonstrating the anticancer properties of lentuscin and vancomycin. Using these bacteriocins as single agents or in combination would be effective against drug-resistant cancer cells with specific cytotoxicity. This is the first report on the synergistic anticancer effect of lentuscin (a bacteriocin from S. lentus) with vancomycin.